OPKO Health Files 13D/A Amendment on GeneDx Holdings

TL;DR

OPKO Health filed an update on its GeneDx stake. Details TBD.

AI Summary

OPKO Health, Inc. filed an amendment to its Schedule 13D on September 18, 2024, regarding its beneficial ownership of GeneDx Holdings Corp. The filing indicates a change in the reporting person's holdings, but specific details on the exact nature or extent of the change are not provided in this excerpt. OPKO Health, Inc. is the filer, and GeneDx Holdings Corp. is the subject company.

Why It Matters

This filing signals a potential shift in the ownership structure or strategic interest of OPKO Health in GeneDx Holdings, which could impact the latter's stock performance and corporate direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or changes in control, introducing uncertainty and potential volatility.

Key Players & Entities

• OPKO HEALTH, INC. (company) — Filer of the Schedule 13D/A
• GeneDx Holdings Corp. (company) — Subject company of the Schedule 13D/A
• Sema4 Holdings Corp. (company) — Former name of GeneDx Holdings Corp.
• CM Life Sciences, Inc. (company) — Former name of GeneDx Holdings Corp.

FAQ

Key Financial Figures

• $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $31.50 — the open market at prices ranging from $31.50 to $38.59 per share for an aggregate sa
• $38.59 — market at prices ranging from $31.50 to $38.59 per share for an aggregate sale price o
• $12,053,996 — n aggregate sale price of approximately $12,053,996. ITEM 5. Interest in Securities of
• $29.00 — the open market at prices ranging from $29.00 to $38.59 per share for an aggregate sa
• $41,649,375 — n aggregate sale price of approximately $41,649,375. Sales of GeneDx Common Stock prior to

Filing Documents

• opk20240917_sc13da.htm (SC 13D/A) — 85KB
• 0001437749-24-029481.txt ( ) — 87KB

is amended by adding the following paragraph to the end of the item

Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between August 26, 2024 and September 18, 2024, OPKO sold a total of 330,472 shares of GeneDx Common Stock on the open market at prices ranging from $31.50 to $38.59 per share for an aggregate sale price of approximately $12,053,996. ITEM 5. Interest in Securities of the Issuer.

is deleted in its entirety and replaced with the following text

Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 2,171,674 8.06% ______________ (1) Based on 26,935,897 shares of GeneDx Common Stock of the Issuer outstanding on July 22, 2024, as set forth in the Issuer's Form 10-Q filed with the SEC on July 30, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 7, OPKO sold a total of 1,211,729 shares of GeneDx Common Stock on the open market at prices ranging from $29.00 to $38.59 per share for an aggregate sale price of approximately $41,649,375. Sales of GeneDx Common Stock prior to August 26, 2024 were previously reported in Amendment No. 4, Amendment No. 5, and Amendment No. 6. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Purchase Price Weighted Price Per Share 7/22/24 50,000 $ 1,630,422 $ 32.6088 7/23/24 75,000 $ 2,509,248 $ 33.4566 7/24/24 75,000 $ 2,529,102 $ 33.7214 7/26/24 60,000 $ 2,031,255 $ 33.8543 CUSIP No. 81663L200 Schedule 13D PAGE 4 of 5 7/29/24 50,000 $ 1,692,890 $ 33.8578 7/31/24 88,839 $ 2,976,350 $ 33.5027 8/6/24 12,994 $ 381,427 $ 29.3541 8/8/24 100,000 $ 3.182.380 $ 31.8238 8/12/24 59,787 $ 2,029,811 $ 33.9507 8/13/24 24,987 $ 868,502 $ 34.7582 8/15/24 39,824 $ 1,317,506 $ 33.0832 8/16/24 50,000 $ 1,714,851 $ 34.2970 8/19/24 50,000 $ 1,724,519 $ 34.4904 8/21/24 94,826 $ 3,270,681 $ 34.4914 8/22/24 25,000 $

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: September 18, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration

View Full Filing

View this SC 13D/A filing on SEC EDGAR